Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids

Archives of Ophthalmology

Volumn 129, Issue 4, 2011, Pages 445-452

  Hos, Deniz ^a   Saban, Daniel R ^b   Bock, Felix ^a   Regenfuss, Birgit ^a   Onderka, Jasmine ^a   Masli, Sharmila ^b   Cursiefen, Claus ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; DNA; FLUOROMETHOLONE; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; PREDNISOLONE ACETATE; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; INFLAMMATORY CORNEAL LYMPHANGIOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIGENS, CD44; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, LYMPHATIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUOROMETHOLONE; GLUCOCORTICOIDS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PREDNISOLONE;

EID: 79953848284     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.42     Document Type: Article

References (49)

1. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy. 2007;92:50-57. (Pubitemid 47096896)
2. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103(30):11405-11410. (Pubitemid 44156530)
3. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443(7114):993-997. (Pubitemid 44646176)
4. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22(3):273-281. (Pubitemid 36359171)
5. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea. 2006;25(4):443-447. (Pubitemid 44620130)
6. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242-249. (Pubitemid 32751680)
7. Dietrich T, Bock F, Yuen D, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010; 184(2):535-539.
8. Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol. 2007;52(4):375-396. (Pubitemid 46901076)
9. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37(12):2485- 2494. (Pubitemid 26391286)
10. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126(1):71-77.
11. Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol. 2009;93(8):1075-1080.
12. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8):2666-2673. (Pubitemid 38998863)
13. Hos D, Bock F, Dietrich T, et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci. 2008; 49(5):1836-1842.
14. Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye (Lond). 2008;22(6):761-767. (Pubitemid 351850511)
15. Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye [in German]. Ophthalmologe. 2007;104(4):336-344.
16. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082-4085. (Pubitemid 24139577)
17. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone: inhibition of angiogenesis in vitro and in vivo. Circulation. 1996;94(10): 2566-2571. (Pubitemid 26403587)
18. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5(12):1418-1423.
19. Pakneshan P, Birsner AE, Adini I, Becker CM, D'Amato RJ. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal antiinflammatory drugs. Invest Ophthalmol Vis Sci. 2008;49(9):3909-3913.
20. Gross J, Azizkhan RG, Biswas C, Bruns RR, Hsieh DS, Folkman J. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci U S A. 1981;78(2):1176-1180. (Pubitemid 11102183)
21. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007;171(3):1058-1065. (Pubitemid 47441002)
22. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24(5):587-611. (Pubitemid 40949559)
23. Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2001;239(7):514-521. (Pubitemid 32725422)
24. Nguyen NX, Seitz B, Martus P, Langenbucher A, Cursiefen C. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol. 2007;144(2):318-319. (Pubitemid 47094708)
25. Proia AD, Hirakata A, McInnes JS, Scroggs MW, Parikh I. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res. 1993;57(6):693-698. (Pubitemid 24039473)
26. Boneham GC, Collin HB. Steroid inhibition of limbal blood and lymphatic vascular cell growth. Curr Eye Res. 1995;14(1):1-10.
27. Greco KV, Lara PF, Oliveira-Filho RM, Greco RV, Sudo-Hayashi LS. Lymphatic regeneration across an incisional wound: inhibition by dexamethasone and aspirin, and acceleration by amicronized purified flavonoid fraction. Eur J Pharmacol. 2006;551(1-3):131-142. (Pubitemid 44648056)
28. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7):1040-1050. (Pubitemid 38544126)
29. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48(6):2545-2552. (Pubitemid 351261204)
30. McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76(11):681-684.
31. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res. 2008;87(5):462-470.
32. Saban DR, Chauhan SK, Zhang X, El Annan J, Jin Y, Dana R. "Chimeric" grafts assembled from multiple allodisparate donors enjoy enhanced transplant survival. Am J Transplant. 2009;9(3):473-482.
33. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J Immunol. 1998;160 (4):1589-1597. (Pubitemid 28106442)
34. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005; 115(9):2363-2372. (Pubitemid 41266198)
35. Austyn JM, Gordon S. F4/80, amonoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981;11(10):805-815. (Pubitemid 12237981)
36. McKnight AJ, Gordon S. The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol. 1998;63(3):271-280. (Pubitemid 28106839)
37. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17(4):403-409. (Pubitemid 28307507)
38. Fràter-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987;84(15):5277-5281.
39. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987;329(6140):630-632. (Pubitemid 17140112)
40. Iqbal Z, Watson DG, Midgley JM, Dennison PR, McGhee CN. J Pharm Biomed Anal. 1993;11(11-12):1115-1120.
41. Maguire MG, Stark WJ, Gottsch JD, et al; Collaborative Corneal Transplantation Studies Research Group. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology. 1994;101 (9):1536-1547. (Pubitemid 24347052)
42. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36(11):2176-2185.
43. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438(7070):946-953. (Pubitemid 43093960)
44. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor- 3 mediates induction of corneal alloimmunity. Nat Med. 2004;10(8):813-815. (Pubitemid 39070853)
45. Dana MR. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol. 2006;21(1):19-22.
46. Becker B. The side effects of corticosteroids. Invest Ophthalmol. 1964;3:492-497.
47. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci. 2009;50(5):2095-2102.
48. Bock F, König Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246(2):281-284. (Pubitemid 351149633)
49. Cursiefen C, Bock F, Horn FK, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology. 2009;116(9):1630-1637.